Eyegate Pharmaceuticals, Inc. has received a patent titled enhanced delivery of a therapeutic to ocular tissues through iontophoresis. The patent covers an aqueous dexamethasone formulation comprising dexamethasone phosphate and the use of the formulation for delivering dexamethasone phosphate to ocular tissue via iontophoresis. The Company holds similar patents in the United States, Mexico, Australia and Israel, with applications pending in Europe and Brazil. EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, which is delivered into the ocular tissues though EyeGate's proprietary innovative drug delivery system, the EyeGate II Delivery System. Iontophoresis is capable of delivering substantially higher ocular drug concentrations leading to potentially greater bioavailability and therapeutic effect, therefore reducing the frequency of dosing. The EyeGate II Delivery System has the potential to offer a non-invasive method of drug delivery as an alternative to the current delivery modalities used for treating ocular diseases, such as eye drops and ocular injections. EGP-437 is being evaluated for two indications: An ongoing Phase III Pivotal Trial in anterior uveitis (indication licensed to a subsidiary of Valeant Pharmaceuticals); and a Phase II Trial, to be initiated this quarter, in post cataract surgery pain and inflammation.